Nothing Special   »   [go: up one dir, main page]

EA201800552A1 - METHOD AND COMBINATION FOR THE TREATMENT OF SOLID TUMOR AND THE KIT CONTAINING A COMBINATION - Google Patents

METHOD AND COMBINATION FOR THE TREATMENT OF SOLID TUMOR AND THE KIT CONTAINING A COMBINATION

Info

Publication number
EA201800552A1
EA201800552A1 EA201800552A EA201800552A EA201800552A1 EA 201800552 A1 EA201800552 A1 EA 201800552A1 EA 201800552 A EA201800552 A EA 201800552A EA 201800552 A EA201800552 A EA 201800552A EA 201800552 A1 EA201800552 A1 EA 201800552A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
treatment
solid tumor
kit containing
combination therapy
Prior art date
Application number
EA201800552A
Other languages
Russian (ru)
Inventor
Дэниел С. Маневал
Эйч. Майкл Шепард
Картис Б. Томпсон
Original Assignee
Галозим, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галозим, Инк. filed Critical Галозим, Инк.
Publication of EA201800552A1 publication Critical patent/EA201800552A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем документе предусмотрена комбинированная терапия, содержащая антигиалуроновый агент, такой как конъюгированный с полимером разрушающий гиалуронан фермент, и химиотерапевтический агент, такой как нуклеозидный аналог. Комбинированная терапия может быть использована в способах лечения рака и, в частности, солидных раковых опухолей.This document provides a combination therapy containing an antihyaluronic agent, such as a polymer conjugated hyaluronan-degrading enzyme, and a chemotherapeutic agent, such as a nucleoside analogue. Combination therapy can be used in methods for treating cancer and, in particular, solid cancer tumors.

EA201800552A 2012-10-16 2013-03-15 METHOD AND COMBINATION FOR THE TREATMENT OF SOLID TUMOR AND THE KIT CONTAINING A COMBINATION EA201800552A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261714719P 2012-10-16 2012-10-16

Publications (1)

Publication Number Publication Date
EA201800552A1 true EA201800552A1 (en) 2019-03-29

Family

ID=65950002

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800552A EA201800552A1 (en) 2012-10-16 2013-03-15 METHOD AND COMBINATION FOR THE TREATMENT OF SOLID TUMOR AND THE KIT CONTAINING A COMBINATION

Country Status (1)

Country Link
EA (1) EA201800552A1 (en)

Similar Documents

Publication Publication Date Title
EA201401096A1 (en) COMBINATION THERAPY, INCLUDING ANTIHYALURONANE AGENT AND TAXAN, AIMED AT THE TREATMENT TARGET
EA201691866A1 (en) TUMOR LYMPHOCYTES PERMITTING FOR ADAPTIVE CELL THERAPY
EA201591674A1 (en) ANTI-TRACT VACCINES AND TREATMENT METHODS WITH THEIR APPLICATION
EA201890961A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT NORROFORMATION
EA201890957A1 (en) COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMORS
EA201792191A1 (en) FGFR / PD-1 COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMOR
EA201300171A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
AU2018278311A1 (en) IRE1 small molecule inhibitors
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2019004193A (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer.
EA201300810A1 (en) ANTI-TRACT THERAPY USING DOUBLE INHIBITORS KINAZ AURORA / MEK
CL2015002807A1 (en) Combination therapy
MX2015006478A (en) Glutamase inhibitors and method of use.
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
MX2019012464A (en) Combination therapy with an anti-axl antibody-drug conjugate.
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2016002051A (en) Methods and kits for the molecular subtyping of tumors.
EA201591543A1 (en) COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
EA201492187A1 (en) METHODS OF TREATMENT OF SOLID TUMORS USING COFERMENT Q10
EA202191257A1 (en) ANTI-CANCER THERAPY BASED ON IMMUNOCYTES BINDING LIV1
MX2019002925A (en) Immune modulation with tlr9 agonists for cancer treatment.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
MX2016009655A (en) Novel methods for treating cancer.
MX2019008233A (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy.